FTY720 for cancer therapy (Review).

Abstract

2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720) is a potent immunosuppressant which has been approved by the Food and Drug Administration (FDA) as a new treatment for multiple sclerosis. As an immunosuppressant, it displays its anti-multiple sclerosis, immunosuppressive effects by activating sphingosine-1-phosphate receptors (S1PRs). In addition to the immunosuppressive effects, FTY720 also shows preclinical antitumor efficacy in several cancer models. In most cases, phosphorylation of FTY720 is not required for its cytotoxic effect, indicating the involvement of S1PR-independent mechanisms which are starkly different from the immunosuppressive property of FTY720. In the present study, we reviewed the rapidly advancing field of FTY720 in cancer therapy as well as some molecular targets of the unphosphorylated form of FTY720.

• Authors: Li Zhang, Han-Dong Wang, Xiang-Jun Ji, Zi-Xiang Cong, Jian-Hong Zhu, Yuan Zhou
• Journal: Oncology reports (Oncol Rep) Vol. 30 Issue 6 Pg. 2571-8 (Dec 2013) ISSN: 1791-2431 [Electronic] Greece
• PMID: 24100923 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Immunosuppressive Agents
• Propylene Glycols
• Receptors, Lysosphingolipid
• Fingolimod Hydrochloride
• Sphingosine

Topics

• Fingolimod Hydrochloride
• Humans
• Immunosuppressive Agents (therapeutic use)
• Multiple Sclerosis (drug therapy, pathology)
• Neoplasms (drug therapy, genetics, pathology)
• Phosphorylation
• Propylene Glycols (therapeutic use)
• Receptors, Lysosphingolipid (genetics, metabolism)
• Sphingosine (analogs & derivatives, therapeutic use)
• United States
• United States Food and Drug Administration